Luis Eduardo López Cortés-rekin lankidetzan egindako argitalpenak (27)

2024

  1. Association of microbiological factors with mortality in Escherichia coli bacteraemia presenting with sepsis/septic shock: a prospective cohort study

    Clinical Microbiology and Infection

  2. Mortality impact of further delays in active targeted antibiotic therapy in bacteraemic patients that did not receive initial active empiric treatment: Results from the prospective, multicentre cohort PROBAC

    International Journal of Infectious Diseases, Vol. 145

  3. Whole-genome characterisation of Escherichia coli isolates from patients with bacteraemia presenting with sepsis or septic shock in Spain: a multicentre cross-sectional study

    The Lancet Microbe, Vol. 5, Núm. 4, pp. e390-e399

2023

  1. Cloxacillin plus fosfomycin versus cloxacillin alone for methicillin-susceptible Staphylococcus aureus bacteremia: a randomized trial

    Nature Medicine, Vol. 29, Núm. 10, pp. 2518-2525

  2. Contemporary use of cefazolin for MSSA infective endocarditis: analysis of a national prospective cohort

    International Journal of Infectious Diseases, Vol. 137, pp. 134-143

  3. Randomized Clinical Trial of the Need for Antibiotic Treatment for Low-Risk Catheter-Related Bloodstream Infection Caused by Coagulase-Negative Staphylococci

    Antibiotics, Vol. 12, Núm. 5

2022

  1. Outpatient Parenteral Antibiotic Treatment vs Hospitalization for Infective Endocarditis: Validation of the OPAT-GAMES Criteria

    Open Forum Infectious Diseases, Vol. 9, Núm. 9

2021

  1. Clinical Features and Outcomes of Streptococcus anginosus Group Infective Endocarditis: A Multicenter Matched Cohort Study

    Open Forum Infectious Diseases, Vol. 8, Núm. 6

  2. Impact of the COVID-19 pandemic on the diagnosis, management and prognosis of infective endocarditis

    Clinical Microbiology and Infection

  3. Multicentre, randomised, open-label, phase IV-III study to evaluate the efficacy of cloxacillin plus fosfomycin versus cloxacillin alone in adult patients with methicillin-susceptible Staphylococcus aureus bacteraemia: Study protocol for the SAFO trial

    BMJ Open, Vol. 11, Núm. 8

  4. Mural Endocarditis: The GAMES Registry Series and Review of the Literature

    Infectious Diseases and Therapy, Vol. 10, Núm. 4, pp. 2749-2764

  5. Prevalence of Colorectal Neoplasms Among Patients With Enterococcus faecalis Endocarditis in the GAMES Cohort (2008–2017)

    Mayo Clinic Proceedings, Vol. 96, Núm. 1, pp. 132-146

2020

  1. A Contemporary Picture of Enterococcal Endocarditis

    Journal of the American College of Cardiology, Vol. 75, Núm. 5, pp. 482-494

  2. An evidence-based bundle improves the quality of care and outcomes of patients with candidaemia

    Journal of Antimicrobial Chemotherapy, Vol. 75, Núm. 3, pp. 730-737

  3. Catheter-related bloodstream infections: predictive factors for Gram-negative bacteria aetiology and 30 day mortality in a multicentre prospective cohort

    The Journal of antimicrobial chemotherapy, Vol. 75, Núm. 10, pp. 3056-3061

  4. Factors associated with the development of septic shock in patients with candidemia: A post hoc analysis from two prospective cohorts

    Critical Care, Vol. 24, Núm. 1

2019

  1. DALBACEN cohort: Dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci

    Annals of Clinical Microbiology and Antimicrobials, Vol. 18, Núm. 1

  2. Mitral valve repair in infective endocarditis is not inferior to valve replacement: results from a Spanish nationwide prospective registry

    General Thoracic and Cardiovascular Surgery, Vol. 67, Núm. 7, pp. 585-593

  3. Rhodomyrtone decreases Staphylococcus aureus SigB activity during exponentially growing phase and inhibits haemolytic activity within membrane vesicles

    Microbial Pathogenesis, Vol. 128, pp. 112-118

  4. Role of age and comorbidities in mortality of patients with infective endocarditis

    European Journal of Internal Medicine, Vol. 64, pp. 63-71